| Name | Title | Contact Details |
|---|
Founded in 1986, eQHealth Solutions is a population health management and technology solutions company that touches millions of lives annually throughout the nation. Our high-tech and high-touch models include innovative technology solutions and care coordination services, and focus on outcomes and optimization of provider and payer networks. eQHealth serves a variety of entities including federal, state and commercial clients.
Fulton County Health Center is a full service hospital and long term care facility located in Wauseon, Ohio. They offer a wide variety of programs and services, including emergency care, surgical department, and general medical care for patients of Wau...
Agility Health is a leading healthcare provider devoted to the rehabilitation of our patients' physical injuries and conditions. Established in 1968, Agility Health delivers personalized care through over one million therapy visits annually at more than 155 service sites in 20 states nationwide. Our team is dedicated to providing exceptional value to the patients, clients and partners we serve. Through our innovative clinical services, proven practice management systems and flexible partnerships, we help achieve optimal performance in a variety of settings, including outpatient clinics, hospitals, long-term care facilities and employer work sites. Agility Health is one of the top 10 rehabilitation services companies in the United States, with a strategic vision to become a leading national source for rehabilitation.
Berkeley Premium Nutraceuticals is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.